Indivior Has Some Explaining To Do At R&D Day After Nasal Naloxone Spray Fails To Get FDA OK
This article was originally published in Scrip
News that Indivior PLC's nasal naloxone spray has failed to get FDA approval is a painful setback for the addiction company given that it has already seen two other products delayed this year - and should make the recently spun-off group's Dec. 9 R&D day in New York City that much more interesting.
You may also be interested in...
Advisory committees will weigh adequacy of current pharmacokinetic requirements and pediatric dosing for novel formulations of the opioid overdose reversal agent.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.